Results 11 to 20 of about 75,048 (254)
Journal of Diabetes Investigation, 2020 Aims/Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are used for treatment of type 2 diabetes mellitus worldwide. However, some patients do not respond well to the therapy, and caution must be taken for certain patients, including those
Takaaki Murakami +5 more
doaj +1 more source
Recent Progress in Hormone Research, 2001 There is a progressive impairment in beta-cell function with age. As a result, 19 percent of the U.S. population over the age of 65 is diagnosed with type 2 diabetes mellitus (DM). Glucagon-like peptide-1 (GLP-1) is a potent insulin secretagogue that has multiple synergetic effects on the glucose-dependent insulin secretion pathways of the beta-cell ...
M E, Doyle, J M, Egan
openaire +2 more sources
Frontiers in Endocrinology, 2021 ObjectiveNon-alcoholic fatty liver disease is highly prevalent in patients with type 2 diabetes mellitus. Studies on glucagon-like peptide-1 receptor agonists for the treatment of non-alcoholic fatty liver disease have reported promising results. Despite
Chloe Wong +12 more
doaj +1 more source
Equine glucagon-like peptide-1 receptor physiology [PDF]
PeerJ, 2018 Background Equine metabolic syndrome (EMS) is associated with insulin dysregulation, which often manifests as post-prandial hyperinsulinemia. Circulating concentrations of the incretin hormone, glucagon-like peptide-1 (GLP-1) correlate with an increased ...
Murad H. Kheder +4 more
doaj +2 more sources
Glucagon-Like Peptide-1 and Diabetes [PDF]
Experimental Diabetes Research, 2011 This special issue was focused on the role and the effects of glucagon-like peptide-1 (GLP-1) in type 2 diabetes. This gastrointestinal hormone, which is mainly secreted after meals, enhances glucose-stimulated insulin release and inhibits food intake.
openaire +2 more sources
Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1
International Journal of Endocrinology, 2015 The glucagon-like peptide-1 is secreted by intestinal L cells in response to nutrient ingestion. It regulates the secretion and sensitivity of insulin while suppressing glucagon secretion and decreasing postprandial glucose levels.
XingChun Wang +4 more
doaj +1 more source
Journal of Cardiovascular Development and Disease, 2023 Background: Calcific aortic valve disease (CAVD) is a significant cause of morbidity and mortality among elderly people. However, no effective medications have been approved to slow or prevent the progression of CAVD.
Yangzhao Zhou +10 more
doaj +1 more source
Physiological Reports, 2017 Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone increasing postprandial insulin release. GLP‐1 also induces diuresis and natriuresis in humans and rodents. The GLP‐1 receptor is extensively expressed in the renal vascular tree in normotensive rats
Jonas Ronn +4 more
doaj +1 more source
Glucagon Like Peptide 1 and Evidence Around Diabetes Specific Nutrition
World Nutrition, 2019 There has been significant research and development in pharmaco-therapeutic molecules for management of type 2 diabetes mellitus (T2DM). Diabetes specific nutrition intervention & newer incretin-based therapies have gained a lot of attention.
ANSHU JOSHI, SAMEER RAO, GANESH KADHE
doaj +1 more source
Expression of Glucagon-Like Peptide 1 Receptor during Osteogenic Differentiation of Adipose-Derived Stem Cells [PDF]
Endocrinology and Metabolism, 2014 BackgroundGlucagon-like peptide 1 (GLP-1), an incretin hormone well known for its glucose-lowering effect, was recently reported to exert an anabolic effect on bone. Although the exact mechanism is not known, it likely involves the GLP-1 receptor (GLP-1R)
Yun Kyung Jeon +10 more
doaj +1 more source